Citigroup Inc. Buys 64,298 Shares of Haleon PLC Sponsored ADR $HLN

Citigroup Inc. raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 7.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 986,450 shares of the company’s stock after acquiring an additional 64,298 shares during the period. Citigroup Inc.’s holdings in Haleon were worth $8,848,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE raised its stake in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. JPMorgan Chase & Co. grew its position in Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after buying an additional 3,207,986 shares during the period. Acadian Asset Management LLC grew its position in shares of Haleon by 3,031.5% during the 2nd quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock valued at $55,813,000 after acquiring an additional 5,212,711 shares during the period. Raymond James Financial Inc. increased its position in Haleon by 0.7% in the second quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock worth $44,748,000 after buying an additional 29,287 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its holdings in Haleon by 11.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,783,907 shares of the company’s stock worth $28,869,000 after acquiring an additional 294,969 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a report on Monday, December 15th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Haleon presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Stock Performance

Haleon stock opened at $11.06 on Monday. The stock has a market cap of $49.23 billion, a price-to-earnings ratio of 28.35 and a beta of 0.18. The stock’s 50 day simple moving average is $10.46 and its two-hundred day simple moving average is $9.82. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92.

Haleon Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio (DPR) is currently 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.